Literature DB >> 1313134

Sigma (sigma) antagonist BMY 14802 prevents methamphetamine-induced sensitization.

H Ujike1, A Kanzaki, K Okumura, K Akiyama, S Otsuki.   

Abstract

We have demonstrated for the first time that the sigma antagonist BMY 14802 prevents the development of behavioral sensitization induced by repeated administration of methamphetamine. Rats received an intraperitoneal injection of 15 or 30 mg/kg BMY 14802 followed by 2 mg/kg methamphetamine 30 min later. Unlike dopamine antagonists, BMY 14802 did not induce major changes in the acute motor effects of 2 mg/kg methamphetamine. Repeated administration of methamphetamine induced progressive augmentation of stereotyped behaviors and resulted in behavioral sensitization. However, repeated administration of methamphetamine in combination with BMY 14802 at either dose produced no increase in the intensity of stereotypy when compared with the first treatment. After a 7-day abstinence period, a challenge test with methamphetamine alone revealed supersensitivity of methamphetamine-sensitized rats to subsequent methamphetamine, whereas rats pretreated with repeated methamphetamine in combination with BMY 14802 exhibited no difference in the intensity of stereotypy from rats pretreated with repeated saline. These results suggest that sigma receptors play a crucial role in the induction of methamphetamine-induced sensitization.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1313134     DOI: 10.1016/0024-3205(92)90466-3

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  22 in total

1.  The sigma receptor agonist SA4503 both attenuates and enhances the effects of methamphetamine.

Authors:  Kelli R Rodvelt; Clark E Oelrichs; Lucas R Blount; Kuo-Hsien Fan; Susan Z Lever; John R Lever; Dennis K Miller
Journal:  Drug Alcohol Depend       Date:  2011-02-01       Impact factor: 4.492

Review 2.  Sigma receptors: biology and therapeutic potential.

Authors:  Xavier Guitart; Xavier Codony; Xavier Monroy
Journal:  Psychopharmacology (Berl)       Date:  2004-06-10       Impact factor: 4.530

3.  Sigma1 receptor antagonists determine the behavioral pattern of the methamphetamine-induced stereotypy in mice.

Authors:  J Kitanaka; N Kitanaka; T Tatsuta; F S Hall; G R Uhl; K Tanaka; N Nishiyama; Y Morita; M Takemura
Journal:  Psychopharmacology (Berl)       Date:  2008-12-04       Impact factor: 4.530

4.  SN79, a sigma receptor antagonist, attenuates methamphetamine-induced astrogliosis through a blockade of OSMR/gp130 signaling and STAT3 phosphorylation.

Authors:  Matthew J Robson; Ryan C Turner; Zachary J Naser; Christopher R McCurdy; James P O'Callaghan; Jason D Huber; Rae R Matsumoto
Journal:  Exp Neurol       Date:  2014-02-06       Impact factor: 5.330

Review 5.  The sigma-1 receptor as a regulator of dopamine neurotransmission: A potential therapeutic target for methamphetamine addiction.

Authors:  Danielle O Sambo; Joseph J Lebowitz; Habibeh Khoshbouei
Journal:  Pharmacol Ther       Date:  2018-01-31       Impact factor: 12.310

Review 6.  Role of microglia in methamphetamine-induced neurotoxicity.

Authors:  Enquan Xu; Jianuo Liu; Han Liu; Xiaobei Wang; Huangui Xiong
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2017-06-15

7.  Selective reduction of alcohol drinking in Sardinian alcohol-preferring rats by a sigma-1 receptor antagonist.

Authors:  Valentina Sabino; Pietro Cottone; Yu Zhao; Luca Steardo; George F Koob; Eric P Zorrilla
Journal:  Psychopharmacology (Berl)       Date:  2009-05-14       Impact factor: 4.530

8.  Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias.

Authors:  Melanie A Paquette; Elizabeth G Brudney; Daniel B Putterman; Charles K Meshul; Steven W Johnson; Stephen Paul Berger
Journal:  Neuroreport       Date:  2008-01-08       Impact factor: 1.837

9.  The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism.

Authors:  Melanie A Paquette; Katherine Foley; Elizabeth G Brudney; Charles K Meshul; Steven W Johnson; S Paul Berger
Journal:  Psychopharmacology (Berl)       Date:  2009-03-13       Impact factor: 4.530

10.  Pharmacology and therapeutic potential of sigma(1) receptor ligands.

Authors:  E J Cobos; J M Entrena; F R Nieto; C M Cendán; E Del Pozo
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.